Sionna Therapeutics (NASDAQ:SION) Director Orbimed Advisors Llc Sells 85,918 Shares of Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 85,918 shares of Sionna Therapeutics stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total value of $3,854,281.48. Following the completion of the transaction, the director owned 2,469,959 shares in the company, valued at approximately $110,802,360.74. This represents a 3.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Orbimed Advisors Llc also recently made the following trade(s):

• On Tuesday, June 30th, Orbimed Advisors Llc sold 115,844 shares of Sionna Therapeutics stock. The shares were sold at an average price of $45.50, for a total value of $5,270,902.00.
• On Wednesday, May 27th, Orbimed Advisors Llc sold 101 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total value of $4,493.49.
• On Monday, May 11th, Orbimed Advisors Llc sold 184,639 shares of Sionna Therapeutics stock. The shares were sold at an average price of $46.22, for a total transaction of $8,534,014.58.
• On Friday, May 8th, Orbimed Advisors Llc sold 59,767 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.58, for a total transaction of $2,664,412.86.
• On Thursday, May 7th, Orbimed Advisors Llc sold 48,546 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.61, for a total transaction of $2,165,637.06.
• On Saturday, April 18th, Orbimed Advisors Llc sold 2,948 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.52, for a total transaction of $131,244.96.
• On Friday, April 17th, Orbimed Advisors Llc sold 52,397 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.68, for a total transaction of $2,341,097.96.
• On Thursday, April 16th, Orbimed Advisors Llc sold 226,906 shares of Sionna Therapeutics stock. The stock was sold at an average price of $45.34, for a total transaction of $10,287,918.04.
• On Wednesday, April 15th, Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32.
• On Tuesday, April 14th, Orbimed Advisors Llc sold 47,814 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.51, for a total value of $2,128,201.14.

Sionna Therapeutics Stock Up 2.1%

NASDAQ SION opened at $44.94 on Friday. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of -23.28 and a beta of 1.33. Sionna Therapeutics, Inc. has a twelve month low of $16.38 and a twelve month high of $48.44. The stock has a fifty day simple moving average of $40.28 and a 200 day simple moving average of $39.54.

Sionna Therapeutics (NASDAQ:SION) last announced its earnings results on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.08). Research analysts expect that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sionna Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Deutsche Bank AG increased its stake in shares of Sionna Therapeutics by 4.5% in the 4th quarter. Deutsche Bank AG now owns 10,029 shares of the company’s stock valued at $413,000 after acquiring an additional 433 shares in the last quarter. Bank of America Corp DE boosted its stake in Sionna Therapeutics by 8.8% during the third quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock worth $192,000 after acquiring an additional 529 shares in the last quarter. MetLife Investment Management LLC grew its holdings in Sionna Therapeutics by 6.6% in the fourth quarter. MetLife Investment Management LLC now owns 8,565 shares of the company’s stock worth $352,000 after purchasing an additional 532 shares during the period. BNP Paribas Financial Markets grew its holdings in Sionna Therapeutics by 35.2% in the third quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock worth $70,000 after purchasing an additional 619 shares during the period. Finally, GF Fund Management CO. LTD. bought a new stake in Sionna Therapeutics in the fourth quarter valued at $36,000.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Stifel Nicolaus increased their target price on shares of Sionna Therapeutics from $44.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, May 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday, May 8th. JonesTrading increased their price objective on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. BTIG Research reissued a “buy” rating and set a $58.00 target price on shares of Sionna Therapeutics in a research note on Wednesday, May 13th. Finally, Freedom Capital downgraded shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 20th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Sionna Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $53.22.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.